occurs naturally in some foods and has been used as a avoring agent in food products. It is used synthetically in the production of polymers and resins. It has also been reported to be a minor metabolite of styrene in rats and humans. Varying doses of 4-vinylpheno l were administered ip to mice. Hepatotoxicity was assessed by measuring serum sorbitol dehydrogenas e (SDH) and by light microscopy. Pneumotoxicity was assessed by measuring proteins, cells, and lactate dehydrogenas e activity in bronchoalveola r lavage uid (BALF) and by light microscopy. 4-VP caused a dose-dependen t increase in serum SDH and mild hepatocellular swelling. It caused an increase in cell number and lactate dehydrogenas e activity in BALF. Microscopically, there was widespread and severe necrosis of the bronchioles by 12 hours. Re-epithelialzation of the bronchioles was evident by 48 hours. These studies indicate that 4-vinylphenol is both hepatotoxi c and pneumotoxic.
INTRODUCTION
The compound 4-vinylphenol (4-hydroxystyrene, 4-ethenylphenol) is a naturally occurring chemical found in coffee, peanuts, and wild rice (2, 25) ; 4-vinylphenol (4-VP) has been used as a avoring agent in a wide variety of food products (6) . It is also used synthetically in the production of polymers and resins. Of particular interest is that 4-VP has been identi ed as a metabolite of styrene. Bakke and Scheline (1) reported nding 4-VP in the hydrolyzed urine of rats dosed orally with styrene. It amounted to 0.1% of the administered dose. Pantarotto et al (17) identi ed small amounts of 4-VP in the urine of rats administered styrene intraperitoneally. They also found 4-hydroxymandeli c acid and 4-hydroxybenzoic acid similar to the end products from styrene metabolism via the styrene oxide pathway. Also, 4-VP was determined to be a minor metabolite in the urine of workers occupationally exposed to styrene (18) .
In a short communication, Watabe et al (24) reported the formation of 4-VP using 14 C-labelled styrene and a rat hepatic microsomal preparation. They suggested that the 4-VP was formed via the 3,4-oxide and was further metabolized to 4-hydroxystyrene-7,8-glycol . In recent studies we were unable to demonstrate the formation of 4-VP from styrene in rodent microsomal preparations but found that 4-VP was rapidly metabolized by mouse and rat hepatic and pulmonary microsomes involving CYP2E1 and CYP2F2 (7) . In a recent study in which rats and mice were exposed by inhalation to [ring-U-14 C]styrene, Boogaard et al (5) reported nding 14 CO 2 . They suggested that ring hydroxylation may be occurring followed by ring opening. Recent studies in which human volunteers inhaled 13 C 8 -styrene were unable to nd products that could be derived from ring hydroxylation (14) .
Styrene is both hepatotoxic and pneumotoxic in rodents (11, 15, 16) , and its toxicity is usually thought to be associated with the production of styrene oxide (4) . Furthermore, although styrene administration does not cause tumors in rats (9), lung tumors have been observed in mice by Ponomarkov and Tomatis (19) and Cruzan et al (8) . Cruzan et al (10) examined the effect of inhaled styrene on the lungs of mice. In mice exposed to 50 to 200 ppm styrene, histopathology revealed a decreased eosinophilia of the bronchial epithelium accompanied by focal crowding of nonciliated cells. They also found an increase in cell proliferation (BrdU labeling) at 2, 5, and 13 weeks of exposure. A similar picture was observed by Green et al (13) in mice exposed to 40 and 160 ppm styrene for up to 10 days. There was a loss of cytoplasm and focal crowding of nonciliated epithelial cells in the bronchioles that was accompanied by an increase in cell replication rates. Evidence of necrosis and loss of cells, believed to be Clara cells, from the large bronchioles was seen immediately following a 6-hour exposure to 40 ppm styrene. The possible contribution of 4-VP as an active metabolite of styrene in either the acute or chronic toxicity of styrene is unknown.
Little information on the toxicity of 4-VP is available in the published literature. Berger et al (2) reported that feeding 4-VP at a concentration of 1 mg/g diet for 7 to 12 days resulted in a decrease in the uterine weight of the small rodent Microtus montanus. The RTECS report (21) on 4-VP indicates that 200 mg/kg administered topically to rabbits is corrosive. The purpose of our studies was to characterize the possible hepatotoxicity and pneumotoxicity associated with 4-vinylphenol in mice by making clinical pathology measurements and using histopathology. These endpoints and this species were selected because the lung and liver are known targets of styrene toxicity in mice (8, 9, 10, 11, 13, 15, 16) whereas in rats the pneumotoxicity is not observed (10, 13) . Male mice were used because they are more susceptible to the hepatotoxicity of styrene than are female mice (16) and were used in our previous studies on 4-vinylphenol metabolism (7) and styrene toxicity (11) . Louis, MO) and tap water were allowed ad libitum. All animals were allowed a minimum of 1 week to adapt to the animal facilities and diet before being used in any experiment. The 4-VP (10% in propylene glycol) was obtained from Lancaster Synthesis (Windham, NH). NADH, pyruvate, and tris buffer were from Sigma Chemical Co. (St. Louis, MO). Triethanolamine was from Mallinckrodt (Paris, KY). Fructose was from Fisher Scienti c (Fair Lawn, NJ). All other chemicals were reagent grade or better.
Study Design: Because of the paucity of data regarding the toxicity of 4-VP, initial range nding studies were carried out in groups of 4 mice administered either 200 or 400 mg/kg 4-VP. To examine the toxicity of 4-VP, groups of mice were administered various doses of 4-VP in water IP. These dilutions were made immediately prior to dosing. For the hepatotoxicity studies, groups of 12 mice were administered 50, 100, or 200 mg/kg 4-VP. Twenty-four hours later they were anesthetized with diethyl ether. The abdominal cavity was opened, and the diaphragm was cut. Blood was obtained by cardiac puncture, and pooled from pairs of animals for measurement of sorbitol dehydrogenase (SDH). For the pneumotoxicity studies, groups of 6 to 8 mice were administered 25, 50, or 100 mg/kg 4-VP. The highest dose used was less than in the hepatotoxicity studies because of the high mortality observed at the 200 mg/kg dose in those studies. Bronchoalveolar lavage uid (BALF) was obtained 24 hours after dosing. The mice were anesthetized with sodium pentobarbital, and the abdominal and thoracic cavities were opened. The incision was continued to the neck region to expose the trachea. A nick was made in the trachea, and a small oral feeding needle was inserted and tied in place. The lungs were perfused twice with 0.8 ml of lavage uid for a total of 1.6 ml. This uid consisted of NaCl (145 mM), KCl (5 mM), NaH 2 PO 4 (1.9 mM), Na 2 HPO 4 (9.4 mM) and glucose (5.5 mM) at a pH of 7.4. These protocols and procedures were approved by the Purdue University Animal Care and Use Committee.
Biochemical Analyses: Blood volumes of 1.0-1.5 ml were obtained by pooling samples from 2 mice, and serum was prepared. Serum SDH activity was measured spectrophotometrically by the method of Gerlach (12) . Serum (0.2 ml) and NADH (12 mM) were incubated for 30 minutes at 30 C in triethanolamine buffer (0.2 M, pH 7.4). The reaction was started by addition of 0.3 ml of 72% (w/v) fructose for a nal reaction volume of 3.0 ml. SDH activity was measured by the decrease in absorbance of NADH at 366 nm for 2 minutes. Results are expressed as l mol/min/L serum. When cell counts were made, the number of cells in 100 l l of BALF was counted using a hemocytometer. The remaining BALF was centrifuged at low speed, and the amount of protein determined using the bicinchoninic acid method (17) .
Lactate dehydrogenase (LDH) activity was measured by the spectrophotometric method of Vassault (22) in centrifuged BALF samples from individual mice. BALF uid (0.1 mL), NADH (0.24 mM), and Tris (81 mM)/NaCl (203 mM) buffer (pH 7.2) were incubated for 15 minutes at 30 C. The reaction was initiated by the addition of 0.5 mL pyruvate (9.8 mM) to make a total volume of 3.0 ml. The activity of LDH was measured 30 seconds after the addition of pyruvate by the decrease in absorbance of NADH at 339 nm for 2 minutes using a Shimadzu Model UV160U UV-visible spectrophotometer. Results are expressed as l mol/min/L BALF.
Histopathology: To further evaluate the hepatotoxicity and pneumotoxicity of 4-VP, groups of mice were administered 0, 10, or 100 mg/kg 4-VP IP and were sacri ced by cervical dislocation 12, 24, and 48 hours after dosing. Lung and liver were removed. The lungs were perfused and xed with 10% neutral buffered formalin as was the liver. Fixed tissues were embedded in paraf n, sectioned at 5 l m and stained with hematoxylin and eosin following standard histopathology techniques.
Statistical Analysis: Each assay was replicated as indicated in the individual tables. Values are expressed as mean SE. In comparing the values, an ANOVA was utilized followed by Student Newman-Keuls' test to detect differences among the groups. In each case the level of signi cance selected was p < 0.05.
RESULTS
In the initial dose range nding studies, mice that were administered 400 mg/kg 4-VP IP died in less than 3 hours. At 200 mg/kg, the animals became very lethargic, and some When mice were treated with 4-VP and the BALF collected 24 hours later, there was no increase in protein (Table 2 ). However, there was a signi cant increase in the number of cells found in the uid (Table 3 ). Although no increase was observed in the group receiving 25 mg/kg 4-VP, at 50 mg/kg the number of cells was 3 1 2 times the number in the control BALF, and at 100 mg/kg it was 25 times that of control. Pneumotoxicity was also suggested by the increases in lactate dehydrogenase released into BALF. Again there was a dosedependent increase at 50 and 100 mg/kg, but at 25 mg/kg there was no signi cant difference from control (Table 4) .
No gross lesions were noted in the major abdominal or thoracic organs of any of the control or treatment group animals. Microscopically, lesions were noted in the lungs from all of the animals in the 3 (12-hour, 24-hour, and 48-hour) high-dose (100 mg/kg) groups. The lesions in the earliest high dose group (at 12 hours) were limited to the distal bronchial and bronchiolar epithelium that was characterized as completely necrotic (Figure 1 ). In the 24-hour high-dose group animals, the distal bronchi and bronchioles were partially lined by varying proportions of attenuated or low cuboidal epithelial cells, and their lumens contained sloughed cells and necrotic cellular debris (Figure 2 ). In the 48-hour high-dose group, the distal bronchi and bronchioles were lined by a low cuboidal epithelium, and there was little cellular debris within the lumens (Figure 3 ). In the 48-hour group animals, there was very little evidence of epithelial cell degeneration or necrosis. In the high-dose groups at all three time periods, a mild to moderate in ammatory cell inltrate, neutrophils and fewer macrophages, was associated with some of the affected airways, and it extended into the adjacent alveolar spaces. Liver lesions were nonspeci c and consisted of mild centrilobular hepatocellular swelling.
DISCUSSION
The purpose of these studies was to assess the hepatotoxicity and pneumotoxicity of 4-VP, a chemical of interest as a natural product, an agent used in the production of polymers and resins, and a putative metabolite of styrene.
The contribution of 4-VP as a metabolite of styrene to the toxicity of styrene is problematical. In a previous in vitro study we were unable to identify it as a metabolite of styrene (7) , but it has been reported in a limited number of studies as a minor urinary metabolite in rodents (1, 17) and humans (18) . It is interesting to note that newer studies by Boogaard et al (5) also suggest that this pathway is operative in mice since 14 ring labeled 14 C-styrene. The authors reasoned that the only way to release this ring carbon was via an initial epoxidation followed by ring opening. On the other hand, Johanson et al (14) found no evidence of metabolites that would be derived from ring labeling in human volunteers inhaling 13 C 8 -styrene.
The studies reported here indicate that increases in serum SDH were observed in doses as low as 50 mg/kg. In contrast, doses of styrene as high as 500 to 1,000 mg/kg were needed to cause a similar effect (11) . Even for styrene oxide, doses of approximately 300 mg/kg were needed. Thus, 4-VP is an order of magnitude more potent than either styrene or styrene oxide. The BALF studies indicate that 4-VP is also pneumotoxic. Increases in cell numbers as well as the release of lactate dehydrogenase into these lungs were readily observed at a 4-VP dose of 50 mg/kg. Again 4-VP was more potent than either styrene or styrene oxide (11) . However, it Vol. 30, No. 5, 2002 still remains unknown if 4-VP contributes to the toxicity of styrene.
The toxic effects of 4-VP on the lung were substantiated by the microscopic ndings of severe necrosis of the distal bronchi and bronchioles by 12 hours followed by a re-epithelialzation with attenuated or low cuboidal cells by 24 hours. By 48 hours there was minimal evidence of cell degeneration or necrosis. This lesion in the bronchioles appears to be similar to that described by Van Winkle et al (23) for naphthalene. They described the swelling, vacuolation, and exfoliation of Clara cells leading to denuding of some regions of the basal lamina in the distal airways within 24 hours followed by repair of the normal architecture.
Interestingly, when the liver was examined by light microscopy there was minimal damage due to 4-VP. The liver lesions were nonspeci c with only mild swelling of the centrilobular hepatocytes. In previous studies with styrene administered by IP injection, we observed hepatocellular damage around the central vein with hepatocytes demonstrating a loss of cytoplasmic staining and mild swelling (11) . Extensive hepatic damage has also been demonstrated in the studies of Morgan et al (16) who reported nding severe congestion and necrosis in the livers of mice exposed to styrene (250 or 500 ppm) by inhalation for 14 days. This was accompanied by increases in serum alanine aminotransferase and sorbitol dehydrogenase.
In summary, the administration of 4-VP caused both hepatic and pulmonary damage as evidenced by increases in serum enzymes and increases in cells and lactate dehydrogenase activity in BALF. The microscopic lesions were predominantly in the distal bronchi and bronchioles of the lung where extensive necrosis occurred with substantial recovery by 48 hours.
